| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Moghrabi Dina Chaya last filed a Form 4 in May 2022, as Director at SPRB. Moghrabi Dina Chaya's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 2,161,022 shares of SPRB. Net of sales, the SPRB filings show accumulation of 250,000 shares.
Moghrabi Dina Chaya has 3 Form 4 filings on record from October 2020 to May 2022, all as Director at Spruce Biosciences (SPRB), 2020–2022.
The 4 reported transactions were 2 option or other derivative awards, 1 conversion and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $3.8M and no sales.
The only open-market purchase was 250,000 shares of SPRB at an average $15.00 on October 14, 2020, about $3.8M.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2020 | SPRB Spruce Biosciences, Inc. | Director | Buy | 250,000 | $15.00 | $3,750,000.00 | +13.1% |